Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-01-18
1996-01-02
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 514 21, 424 852, 530385, A61K 3842
Patent
active
054808669
ABSTRACT:
The invention is directed to a method for the prophylaxis or treatment of an animal for deleterious physiological effects such as systemic hypotension caused by nitric oxide production induced by a biological response modifier. Examples of such biological response modifiers include but are not limited to a cytokine and an endotoxin. The invention is also directed to a method for the treatment of septic shock. Hemoproteins such as hemoglobin, myoglobin, hemalbumin and methemalbumin, for example, are useful when administered to a hypotensive patient.
REFERENCES:
patent: 4061736 (1977-12-01), Morris et al.
patent: 4584130 (1986-04-01), Bucci et al.
patent: 4598064 (1986-07-01), Walder
patent: 4751068 (1988-06-01), Bickar et al.
patent: 5028627 (1991-07-01), Kilbourn et al.
patent: 5082642 (1992-01-01), Bickar et al.
patent: 5296466 (1994-03-01), Kilbourn et al.
Bone, Roger C., Annals of Internal Medicine, vol. 115(6), pp. 457-469, 1991.
Glauser, M. P. et al, The Lancet, vol. 338, pp. 732-736, 1991.
Kilbourn, Robert G. et al., Journ. of the National Cancer Institute, vol. 84(11), pp. 827-831, 1992.
Natanson, Charles et al., Annals of Internal Medicine, vol. 120(9), pp. 771-783, 1994.
The Economist, "Panic in the Petri Dish," pp. 61-62, Jul. 23.
Cross, Alan S. et al., Infection and Immunity, vol. 61, No. 7, pp. 2741-2747, Jul. 1993.
Petros, Andy et al., The Lancet, vol. 338, pp. 1557-1558, 1991.
Kilbourn et al., "N.sup.G -Methyl-L-arginine Inhibits Tumor Necrosis Factor-Induced Hypotension: Implications for the Involvement of Nitric Oxide," Proc. Natl. Acad. Sci. USA, 87:3629-3632, 1990.
Palmer et al., "Nitric Oxide Release Accounts for the Biological Activity of Endothelium-Derived Relaxing Factor," Nature, 327:524-526, 1987.
Moncada et al., "Generation of Prostacycline and Endothelium-Derived Relaxing Factor from Endothelial Cells," IN: Golles, G., Legran J. Y., and Nurden A. eds., Biology and Pathology of Platelets-Vessel Wall Interactions, pp. 289-304, 1986.
Kilbourn et al., "Activated Macrophages Secrete a Soluble Factor that Inhibits Mitochondrial Respiration of Tumor Cells," The Journal of Immunology, 133(5) :2577-2581, 1984.
Kilbourn & Belloni, "Endothelial Cell Production of Nitrogen Oxides in Response to Interferon .gamma. in Combination with Tumor Necrosis Factor, Interleukin-1, or Endotoxin," Journal of the National Cancer Institute, 82:772-776, 1990.
Aisaka et al., "N.sup.G -Methylarginine, an Inhibitor of Endothelium-Derived Nitric Oxide Synthesis, is a Potent Pressor Agent in the Guinea Pig: Does Nitric Oxide Regulate Blood Pressure in Vivo?" Biochemical and Biophysical Research Communications, 160(2) :881-886, 1989.
Vallance et al., "Effects of Endothelium-Derived Nitric Oxide on Peripheral Arteriolar Tone in Man," Lancet, 28:997-999, 1989.
Kilbourn et al., "Reversal of Endotoxin-Mediated Shock by N.sup.G -Methyl-L-Arginine, an Inhibitor of Nitric Oxide Synthesis," Biochemical and Biophysical Research Communications, 172(3) :1132-1138, 1990.
Gross et al., "Cytokine-activated Endothelial Cells Express and Isotype of Nitric Oxide Synthase Which is Tetrahydrobiopterin-Dependent. Calmodulin-Independent and Inhibited by Arginine Analogs with a Rank-Order of Potency Characteristic of Activated Macrophages," Biochemical and Biophysical Research Communications, 178(3):823-829, 1991.
Schmidt et al., "Insulin Secretion from Pancreatic B Cells Caused by L-Arginine-Derived Nitrogen Oxides," Science, 255:721-723, 1992.
Sakuma et al., "Identification of Arginine as a Precursor of Endothelium-Derived Relaxing Factor," Proc. Natl. Acad. Sci. USA, 85:8664-8667, 1988.
Stuehr & Marletta, "Induction of Nitrite/Nitrate Synthesis in Murine Macrophages by BCG Infections, Lymphokines, or Interferon-.gamma.," The Journal of Immunology, 139(2) :518-525, 1987.
Bone, Roger C. "The Pathogenesis of Sepsis," Ann. Int. Med. 115:457-469, 1991.
Bone, Roger C. "A Critical Evaluation of New Agents for the Treatment of Sepsis," JAMA 266(12):1686-1691, 1991.
Glauser, M. P., et al. "Septic Shock: Pathogenesis," The Lancet, 338:732-736, 1991.
Johnston, J. "Molecular Science Sets Its Sights on Septic Shock," J. NIH Res. 3:61-65, 1991.
Moncada, S. and E. A. Higgs, "Endogenous Nitric Oxide: Physiology, Pathology, and Clinical Relevance," Eur. J. Clin. Invest. 21:361-374, 1991.
Moncada, S., et al. "The L-Arginine: Nitric Oxide Pathway," J. Cardiovascular Pharm. 7(Suppl. 3):S1-S9, 1991.
Moncada, S., et al. "Nitric Oxide: Physiology, Pathophysiology, and Pharmacology," Pharmacological Reviews 43 (2):109-142.
Parratt, J. R., and J. C. Stoclet, "Possible Role of Nitric Oxide in Refractory Hypotension Associated with Sepsis and Endotoxaemia and with Multiple Organ Failure," Applied Cardiopulmonary Pathophysiology 4:143-149, 1991.
Snell, R. J., and J. E. Parrillo, "Cardiovascular Dysfunction in Septic Shock," Chest 99(4):1000-1009, 1991.
Wang, Q., et al. "Nitric Oxide Hemoglobin in Mice and Rats in Endotoxic Shock," Life Sciences 49:PL-55-60, 1991.
Bickar et al., "Carbon Monoxide-Driven Reduction of Ferric Heme and Heme Proteins," Journal of Biological Chemistry, 259(17):10777-10783, 1984.
Martin et al,. "Selective Blockade of Endothelium-Dependent and Glyceryl Trinitrate-Induced Relaxation by Hemoglobin and by Methylene Blue in the Rabbit Aorta," The Journal of Pharmacology and Experimental Therapeutics, 232(3):708-716, 1985.
Buga et al., "Endothelium-Derived Nitric Oxide Relaxes Nonvascular Smooth Muscle," European Journal of Pharmacology, 161:61-72, 1989.
Stuehr et al., "Activated Murine Macrophages Secrete a Metabolite of Arginine with the Bioactivity of Endothelium-Derived Relaxing Factor and the Chemical Reactivity of Nitric Oxide," J. Exp. Med., 169:1011-1020, 1989.
Stuehr et al., "Synthesis of Nitrogen Oxides from L-Arginine by Macrophage Cytosol: Requirement for Inducible and Constitutive Components," Biochemical and Biophysical Research Communications, 161(2):420-426, 1989.
Torti et al., "A Macrophage Factor Inhibits Adipocyte Gene Expression: An in Vitro Model of Cachexia," Science, 229:867-871, 1985.
Palmer et al., "Vascular Endothelial Cells Synthesize Nitric Oxide from L-Arginine," Nature, 333:664-666, 1988.
Old, Lloyd J., "Tumor Necrosis Factor (TNF)," 230:630-632, 1985.
Yoshida and Kasama, "Biotransformation of Nitric Oxide," Environmental Health Perspectives, 73:201-206, 1987.
Schmidt et al., "Arginine is a Physiological Precursor of Endothelium-Derived Nitric Oxide," European Journal of Pharmacology, 154:213-216, 1988.
Reif and Simmons, "Nitric Oxide Mediates Iron Release from Ferritin," Archives of Biochemistry and Biophysics, 283(2):537-541, 1990.
Kruszyna et al., "Nitrite Conversion to Nitric Oxide in Red Cells and Its Stabilization as a Nitrosylated Valency Hybrid of Hemoglobin," The Journal of Pharmacology and Experimental Therapeutics, 241(1) :307-313, 1987.
Kosaka et al., "The Interaction Between Nitrogen Oxides and Hemoglobin and Endothelium-Derived Relaxing Factor," Free Radical Biology and Medicine, 7:653-658, 1989.
Chevion et al., "Iron-Nitrosyl Bond configuration in Nitrosyl-Hemoproteins: A Comparative EPR Study of Hemoglobin A and Hemoglobin Kansas," Israel Journal of Chemistry, 15:311-317, 1976.
Collier and Vallance, "Second Messenger Role for NO Widens to Nervous and Immune Systems," Trends in Pharmacological Sciences Including Toxicological Sciences, Elseview Science Publishers, Ltd., front page and pp. 428-431, 1989.
Ignarro et al., "Endothelium-Derived Relaxing Factor Produced and Released from Artery and Vein is Nitric Oxide," Proc. Natl. Acad. Sci. USA, 84:9265-9269, 1987.
Murray et al., "Stabilization and Partial Characterization of Endothelium-Derived Relaxing Factor from Cultured Bovine Aortic Endothelial Cells," Biochemical and Biophysical Research Communications, 141(2):689-696, 1986.
Marletta, Michael A., "Nitric Oxide: Biosynthesis and Biological Significance," name of publication unknown, Elseview Science Publishers, Ltd., pp. 448-493, 1989.
Geokas et al., "Methamalbumin in the Diagnosis of Acute Hemorrhagic Pancreatitis,", Annals of Internal Medicine, 81:483-486, 1974
Bonaventura Joseph
DeAngelo Joseph
Kilbourn Robert G.
Apex Bioscience, Inc.
Board of Regents , The University of Texas System
Duke University
Sayala C.
Wityshyn Michael G.
LandOfFree
Hemoproteins for inhibition of nitric oxide-mediated hypotension does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hemoproteins for inhibition of nitric oxide-mediated hypotension, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hemoproteins for inhibition of nitric oxide-mediated hypotension will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-235193